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Background: A pilot study can be an important step in the assessment of an intervention by 
providing information to design the future definitive trial. Pilot studies can be used to estimate 
the recruitment and retention rates and population variance and to provide preliminary evidence 
of efficacy potential. However, estimation is poor because pilot studies are small, so sensitivity 
analyses for the main trial’s sample size calculations should be undertaken.
Methods: We demonstrate how to carry out easy-to-perform sensitivity analysis for designing 
trials based on pilot data using an example. Furthermore, we introduce rules of thumb for the 
size of the pilot study so that the overall sample size, for both pilot and main trials, is minimized.
Results: The example illustrates how sample size estimates for the main trial can alter dramati-
cally by plausibly varying assumptions. Required sample size for 90% power varied from 392 
to 692 depending on assumptions. Some scenarios were not feasible based on the pilot study 
recruitment and retention rates.
Conclusion: Pilot studies can be used to help design the main trial, but caution should be 
exercised. We recommend the use of sensitivity analyses to assess the robustness of the design 
assumptions for a main trial.
Keywords: pilot, feasibility, sample size, power, randomized controlled trial, sensitivity analysis
Introduction
Prior to a definitive intervention trial, a pilot study may be undertaken. Pilot trials are 
often small versions of the main trial, undertaken to test trial methods and procedures.1,2 
The overall aim of pilot studies is to demonstrate that a future trial can be undertaken. 
To address this aim, there are a number of objectives for a pilot study including assess-
ing recruitment and retention rates, obtaining estimates of parameters required for 
sample size calculation, and providing preliminary evidence of efficacy potential.3–6
We illustrate how to use pilot studies to inform the design of future randomized con-
trolled trials (RCTs) so that the likelihood of answering the research question is high. We 
show how pilot studies can address each of the objectives listed earlier, how to optimally 
design a pilot trial, and how to perform sample size sensitivity analysis. Our example uses 
a continuous outcome, but most of the content can be applied to pilot studies in general.
Considerations for trial design
When designing a definitive trial, one must consider
• The target effect size, such as the difference in means for continuous outcomes;
• The variance about the estimates for continuous outcomes, which is used to give 
a range of responses for individuals in the trial;
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• Feasibility, including referral, recruitment, and retention 
rates.
Pilot trial results can inform each of these elements. Fac-
tors such as type I error and power are set independent of 
the pilot and are discussed in detail elsewhere.7 We focus on 
external pilot studies, where the trial is run before the main 
trial, and results are not combined.8
Feasibility
The first consideration is feasibility: will the researchers be 
able to recruit the required number of participants within 
the study timeframe and retain them in the main trial? While 
review of clinical records can be used to give some indication 
of potential participant pool, pilot studies provide estimates 
of the number of participants that actually enroll and consent 
to randomization, and these estimates should be included in 
the manuscripts that report the pilot study results.9 Many tri-
als struggle to reach their sample size goal, which can result 
in trial extensions or failure to recruit to their prespecified 
sample size.10 Failure to recruit is a major issue in UK publicly 
funded trials, where 45% fail to reach target sample size.10 
Along with review of prior trials at the same centers in similar 
populations, pilot studies can also give estimates of retention 
rates and adherence rates.11 Missing data and dropouts are 
issues in most RCTs12 and need to be considered at each step 
of the research process,13 including design, reporting,9 and 
progression to a larger definitive trial.11,14
7DUJHWHIIHFWVL]HDQGSRWHQWLDOHIÀFDF\
Hislop et al15 undertook a systematic review to identify seven 
approaches for determining the target effect size for an RCT 
and classified them as clinically important and/or realistic. A 
specific type of clinically important difference is the smallest 
value that would make a difference to patients or that could 
change care, a quantity referred to as the minimum important 
difference (MID), or sometimes minimally clinical important 
difference. The MID can be difficult to determine, particularly 
as it can change with patient population. However, research-
ers in various fields have investigated MID estimation and 
provide guidance on estimation.16,17 In the absence of a known 
MID for continuous outcomes, particularly patient-reported 
outcomes, a standardized effect size15 between 0.3 and 0.5 
has been recommended.17,18 Expert opinion is also used to 
specify important differences.15 Although some researchers 
use the pilot effect size to power the definitive trial, this is a 
practice that should be avoided in general, as estimation is 
poor due to the small sample size, and is likely to mislead.19
The target effect size must also be realistic, and the 
estimated effect size and confidence interval (CI) from the 
pilot can give some evidence here, ie, whether there is any 
indication that the intervention is effective and important 
differences might be obtained in the main trial.5 The small 
sample size of a pilot makes estimation uncertain, so cau-
tion must be exercised.19,20 One approach for handling this 
uncertainty is to use significance levels other than the “tra-
ditional” 5% to provide preliminary evidence for efficacy, 
with corresponding CIs such as 85 and 75% in addition to 
95% CIs.21 A figure showing these CIs, the MID, and the 
null value can be a helpful way of displaying pilot results, by 
facilitating an assessment of both statistical significance and 
the potential for clinical significance.31 While some authors 
argue against carrying out hypothesis tests and assessing 
efficacy from pilots, even potential efficacy, most pilot stud-
ies do undertake hypothesis tests.6 We strongly stress that 
preliminary efficacy evidence from a pilot study should not 
be overstated, and researchers should avoid temptation to 
forgo the main trial.20,22
Estimating the standard deviation (SD)
The population SD is another key element of sample size 
estimation for continuous outcomes, and its estimation is 
one of the objectives for conducting a pilot study. However, 
similar to the effect size, the SD can be imprecisely estimated 
due to the pilot’s small sample size. Using a pilot study’s SD 
to design a future sample size has been shown to often result 
in an underpowered study.23,24 Thus, sensitivity analyses 
should be undertaken.
Sensitivity analysis for sample size
Sensitivity analyses are important to assess the robustness 
of study results to the assumptions made in the primary 
analysis.25 Sensitivity analyses should also be performed in 
the design stage26 and can take the form of accounting for the 
uncertainty in estimation by calculating sample sizes based 
on a range of plausible SDs and retention/dropout rates. 
Browne23 suggested using the pilot study’s upper limit of the 
80% CI for the SD to calculate sample size in the subsequent 
trial. One may also consider SDs from the literature.
Pilot study sample size
In order to have the best chance of answering the research 
question, researchers should carefully consider the size of not 
only the definitive trial but also the pilot as well. Although 
traditional power calculations are inappropriate for pilot 
studies (since the primary aim of a pilot study is not to test 
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Using pilots to design main trials
superiority of one treatment over the other), a sample size 
justification is important. While there are several rules of 
thumb for the size of a pilot study, ranging from 12 to 35 
individuals per arm,5,27 none of these guidelines account for 
the likely size of the future trial.
Whitehead et al27 showed how, if you know the main trial’s 
target effect size, you can estimate the pilot study’s optimum 
sample size, minimizing the number of patients recruited 
across the two studies. From this work, they proposed stepped 
rules of thumb for pilot studies based on the target effect size 
and the size of the future trial. These rules are summarized 
in Table 1. For example, if the future trial will be designed 
around a small effect, then the number of patients per arm 
for the pilot study should be 25 for 90% power. Using these 
rules increases the likelihood of appropriate power for the 
future trial. Cocks and Torgerson5 also recommend basing the 
pilot study size on the future trial’s size, if the SD is known.
Example
Suppose a research team is planning a pilot in the anticipation 
of designing a definitive trial. The main trial will be a two-arm 
RCT comparing a new supportive care regimen for cancer 
patients to usual care, with assessments at baseline, 6 weeks, 
and 3 months. Their primary outcome is the quality of life 
at 3 months as measured by the Functional Assessment of 
Cancer Therapy-General (FACT-G), a 27-item questionnaire 
covering aspects of physical, social, family, emotional, and 
functional well-being.28
Pilot study sample size
To use the stepped rules of thumb for pilot sample size, the 
researchers must consider the target effect size and SD for 
the main trial in order to calculate the standardized differ-
ence (effect size). They find that the estimated FACT-G MID 
is between three and six points29 and an SD estimate from 
the literature30 is 14 in similar populations. Using an MID 
estimate of four points, and an SD of 14, the standardized 
effect size is 4/14=0.29. For a 90% powered main trial, they 
should use a sample size of 25 per arm for the pilot (Table 1).
Pilot study results
Suppose now the researchers undertake the pilot study of 
50 participants with recruitment over 2 months. Of the 100 
potential participants, 70 participants were referred by their 
oncologist, 60 participants met eligibility criteria, and 50 
participants agreed to participate. This indicates a recruit-
ment rate of 50% of eligible patients, at 25 recruitments per 
month. Of the 50 participants, 40 participants completed all 
three assessments; retention is 80%. These rates will aid in 
estimating the main trial duration.
The difference in the quality of life between the arms 
at 3 months is estimated at 3.1 points, with 95% CI −1.8 to 
8.0, and SD =11.2. Figure 1 shows several CIs demonstrating 
Table 1 Stepped rules of thumb for pilot study sample size per arm, as a function of the target effect size (standardized difference) 
and power of the main trial
Standardized difference, da 80% powered main trial 90% powered main trial
Pilot N per arm Main trial N per arm Pilot N per arm Main trial N per arm
Extra small (d<0.1) 50 >1571 75 >2103
Small (0.1≤d<0.3) 20 1761571 25 2352103
Medium (0.3≤d<0.7) 10 34176 15 44235 
Large (d≥0.7) 10 ≤34 10 ≤44
Notes: 
a
d
X X
SD
SD
n n
=
−
=
− + −
int int int,
( ) s ( )
ctl
pooled
pooled
ctlwhere 
1 1
2
s
int
ctl
ctl
2
2n n+ − .
 The corresponding likely size of the main trial is also shown. int is the intervention 
arm, and ctl is the control arm.
Figure 1 Mean difference in FACT-G scores between pilot study intervention and 
FRQWURODUPVZLWKFRQÀGHQFHLQWHUYDOV
Abbreviations: FACT-G, Functional Assessment of Cancer Therapy-Genera; MID, 
minimum important difference.
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that the intervention is promising, as each CI contains the 
MID of 4. Thus, the objective of the pilot study to provide 
preliminary evidence of efficacy has been met.
Sample size calculations and sensitivity 
analyses
Table 2 shows sample sizes based on the pilot study’s SD, its 
upper 80% CI limit (taken as the square root of the CI for 
the variance), and the original estimate from the literature. 
Sample sizes are also given for the observed dropout rate 
(20%) and for >5 and <5%. For 90% power, sample size 
ranges from 392 to 692. For 80% power, sample sizes range 
from 296 to 518. Note that the sensitivity analysis is quanti-
fied in terms of the effect of assumptions on the sample size. 
An alternative approach is to fix the sample size (at 392 say) 
and observe how power varies based on assumptions.
Feasibility of the main trial
We now consider feasibility. Specifically, are the researchers 
likely to be able to recruit the required number of participants 
within the study timeframe? Based on the funding and the 
follow-up time of 3 months, recruitment can take 1.5 years. 
If the pilot recruitment rate of 25 participants per month is a 
good estimate, then the study will be able to recruit and enroll 
450 participants. This falls below several of the estimates in 
Table 2. Further consideration may be needed how to expand 
the pool of participants.
Conclusion
We have illustrated how pilot studies can aid in the design 
of future trials with continuous outcomes by providing 
estimates of population SD, evidence of potential for inter-
vention effectiveness, and quantification of feasibility in the 
form of recruitment and retention rates. We have introduced 
guidelines on pilot study sample size and demonstrated 
sample size sensitivity analysis. The example demonstrated 
how main trial sample size estimates can vary dramatically 
by plausibly altering assumptions.
The decision to progress from a pilot trial to a main trial 
is generally made using feasibility estimates, as well as issues 
such as protocol nonadherence. For more information on 
progression, refer to Avery et al,11 and for information on the 
context of internal pilots, refer to Hampson et al.14 Whether 
researchers decide to progress to a definitive trial or not, 
results of pilot studies should be published. A CONSORT 
extension for reporting results of pilot and feasibility studies 
gives detailed guidelines.9
Acknowledgments
This research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sectors. 
The current address of ALW is Southampton Clinical Trials 
Unit, University of Southampton, Southampton, UK.
Disclosure
Professor MLB is supported by the University of Arizona 
Cancer Center, through NCI grant P30CA023074. Professor 
SAJ is funded by the University of Sheffield. Dr ALW was 
funded by a University of Sheffield studentship. The authors 
report no other conflicts of interest in this work.
References
 1. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why 
and how. BMC Med Res Methodol. 2010;10:1.
 2. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or 
feasibility study? A review of current practice and editorial policy. BMC 
Med Res Methodol. 2010;10:67.
Table 2 A range of sample sizes varying dropout, recruitment rate, and estimated SD assuming an effect size of four points
6'MXVWLÀFDWLRQ SD Dropout (%) 90% powered main trial 80%  powered main trial
N 
(total)
Required 
recruitment rate 
per montha
Feasibleb N 
(total)
Required 
recruitment rate 
per montha
Feasibleb
Pilot study SD 11.2 15 392 22 Yes 296 16 Yes
20 416 23 Yes 314 17 Yes
25 444 25 Yes 334 19 Yes
Upper 80% 
FRQÀGHQFHOLPLW
from pilot
13.2 15 542 30 No 406 23 Yes
20 576 32 No 430 24 Yes
25 614 34 No 460 26 No
Literature 14.0 15 610 34 No 458 26 No
20 648 36 No 486 27 No
25 692 38 No 518 29 No
Notes: aBased on 1.5 years of recruitment. bBased on the pilot study recruitment rate of 25 participants per month.
Abbreviation: SD, standard deviation.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
13
9.
88
 o
n 
18
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
157
Using pilots to design main trials
 3. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating com-
plex interventions: the new Medical Research Council guidance. BMJ. 
2008;337:a1655.
 4. Lancaster G, Campbell M, Eldridge S, et al. Trials in primary care: 
statistical issues in the design, conduct and evaluation of complex 
interventions. Stat Methods Med Res. 2010;19(4):349–377.
 5. Cocks K, Torgerson DJ. Sample size calculations for pilot ran-
domized trials: a confidence interval approach. J Clin Epidemiol. 
2013;66(2):197–201.
 6. Shanyinde M, Pickering RM, Weatherall M. Questions asked and 
answered in pilot and feasibility randomized controlled trials. BMC 
Med Res Methodol. 2011;11(1):117.
 7. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 
2004;23(12):1921–1986.
 8. Wittes J, Brittain E. The role of internal pilot studies in increasing the 
efficiency of clinical trials. Stat Med. 1990;9(1–2):65–72.
 9. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 state-
ment: extension to randomised pilot and feasibility trials. BMJ. 
2016;355:i5239.
 10. Sully B, Julious SA, Nicholl J. A reinvestigation of recruitment to 
randomised, controlled, multicenter trials: a review of trials funded by 
two UK funding agencies. Trials. 2013;14:166.
 11. Avery KNL, Williamson PR, Gamble C, et al. Informing efficient ran-
domised controlled trials: exploration of challenges in developing pro-
gression criteria for internal pilot studies. BMJ Open. 2017;7(2):e013537.
 12. Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in 
RCTs; a review of the top medical journals. BMC Med Res Methodol. 
2014;14(1):118.
 13. Bell ML, Fairclough DL. Practical and statistical issues in missing data 
for longitudinal patient-reported outcomes. Stat Methods Med Res. 
2014;23(5):440–459.
 14. Hampson LV, Williamson PR, Wilby MJ, Jaki T. A framework for pro-
spectively defining progression rules for internal pilot studies monitor-
ing recruitment. Stat Methods Med Res. Epub 2017 Jan 01.
 15. Hislop J, Adewuyi TE, Vale LD, et al. Methods for specifying the target 
difference in a randomised controlled trial: the Difference ELicitation in 
TriAls (DELTA) systematic review. PLoS Med. 2014;11(5):e1001645.
 16. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson 
NK. Responsiveness and minimal important differences for patient 
reported outcomes. Health Qual Life Outcomes. 2006;4:70.
 17. King M. A point of minimal important difference (MID): a critique of 
terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 
2011;11(2):171–184.
 18. Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality 
of half a standard deviation: confirmation through another look. Expert 
Rev Pharmacoecon Outcomes Res. 2004;4(5):581–585.
 19. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution 
regarding the use of pilot studies to guide power calculations for study 
proposals. Arch Gen Psychiatry. 2006;63(5):484–489.
 20. Loscalzo J. Pilot trials in clinical research: of what value are they? 
Circulation. 2009;119(13):1694–1696.
 21. Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical inter-
pretation of pilot trials: should significance thresholds be reconsidered? 
BMC Med Res Methodol. 2014;14(1):41.
 22. Lancaster GA, Dodd S, Williamson PR. Design and analysis of 
pilot studies: recommendations for good practice. J Eval Clin Pract. 
2004;10(2):307–312.
 23. Browne RH. On the use of a pilot sample for sample size determination. 
Stat Med. 1995;14(17):1933–1940.
 24. Vickers AJ. Underpowering in randomized trials reporting a sample 
size calculation. J Clin Epidemiol. 2003;56(8):717–720.
 25. Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity 
analyses in clinical trials: the what, why, when and how. BMC Med Res 
Methodol. 2013;13(1):92.
 26. Lewis JA. Statistical principles for clinical trials (ICH E9): an 
introductory note on an international guideline. Stat Med. 1999; 
18(15):1903–1942.
 27. Whitehead A, Julious S, Cooper C, Campbell MJ. Estimating the sample 
size for a pilot randomised trial to minimise the overall trial sample size 
for the external pilot and main trial for a continuous outcome variable. 
Stat Methods Med Res. 2016;25(3):1057–1073.
 28. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of can-
cer therapy scale: development and validation of the general measure. 
J Clin Oncol. 1993;11(3):570–579.
 29. Webster K, Cella D, Yost K. The functional assessment of chronic ill-
ness therapy (FACIT) measurement system: properties, applications, 
and interpretation. Health Qual Life Outcomes. 2003;1:79.
 30. Bell ML, McKenzie JE. Designing psycho-oncology randomised trials 
and cluster randomised trials: variance components and intra-cluster 
correlation of commonly used psychosocial measures. Psychooncology. 
2013;22(8):1738–1747.
 31. Bell, ML, Fiero MH, Dhillon HM, Bray VJ and Vardy JL. Statistical 
controversies in cancer research: using standardized effect size graphs 
to enhance interpretability of cancer-related clinical trials with patient-
reported outcomes. Ann Oncol. 2017;28(8):1730–1733.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
16
7.
13
9.
88
 o
n 
18
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
